{"schema_version":"1","generated_at":"2026-10-29T11:59:36.924Z","data_as_of":"2026-10-27","url":"https://www.findmykol.com/kol/arvind-chaudhry","json_url":"https://www.findmykol.com/kol/arvind-chaudhry/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"arvind-chaudhry","name":"Arvind Chaudhry","credential":"MD","title":"Hematology Oncology (listed specialty)","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Medical Oncology Associates","institution_url":"https://www.findmykol.com/institution/medical-oncology-associates","city":"Spokane","state":"WA","region":{"label":"West","url":"https://www.findmykol.com/region/west"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1750336236","openalex":"A5112566845"},"summary":"Arvind Chaudhry is Hematology Oncology (listed specialty) at Medical Oncology Associates. ClinicalTrials.gov lists 1 registered study with this person as an investigator.","overview":{"text":"Arvind Chaudhry, MD, is Hematology Oncology (listed specialty) at Medical Oncology Associates (Spokane, WA). The public record shows 80 publications with 5,094 citations (h-index 21), centered on Oncology. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 110 companies.","bullets":["Top research focus: Oncology","1 registered trials on ClinicalTrials.gov","Open Payments reporting from 110 companies"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Mucositis","therapeutic_area":"Head & Neck","trials":1,"topics":0,"strength":3}],"research_topics":["Oncology"],"drugs_studied":{"total":12,"shown":3,"withheld":9,"rows":[{"name":"Cabometyx","generic":"Cabozantinib","trials":0,"payments":43,"publications":0,"mentions":43},{"name":"Imbruvica","generic":"Ibrutinib","trials":0,"payments":43,"publications":0,"mentions":43},{"name":"Reblozyl","generic":"Luspatercept","trials":0,"payments":39,"publications":0,"mentions":39}]},"works_with":{"total":30,"shown":3,"withheld":27,"rows":[{"name":"Pfizer Inc.","trials":0,"payments":93,"mentions":93},{"name":"Novartis Pharmaceuticals Corporation","trials":0,"payments":89,"mentions":89},{"name":"E.R. Squibb & Sons, L.L.C.","trials":0,"payments":74,"mentions":74}]}},"scholarship":{"h_index":21,"pubmed_count":0,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT02606994","title":"Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis","phase":"PHASE2","status":"TERMINATED","role":"Investigator","sponsor":"Oral Defense, LLC","source_url":"https://clinicaltrials.gov/study/NCT02606994","trial_url":"https://www.findmykol.com/trial/NCT02606994"}],"source":"trials"},"payments":{"company_count":110,"program_years":{"first":2021,"last":2025},"rows_total":270,"shown":3,"withheld":267,"rows":[{"payer":"Exelixis Inc.","program_year":2025,"amount_usd":4470.05,"payment_count":26,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750336236"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":1510.35,"payment_count":35,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750336236"},{"payer":"Janssen Biotech, Inc.","program_year":2025,"amount_usd":481.75,"payment_count":16,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750336236"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1750336236","source":"payments"},"prescribing":{"data_year":2024,"areas_total":10,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":44.3,"classes_total":13,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":42.6,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":29},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":0.5,"drugs":[{"name":"Imbruvica","share_pct":23.7},{"name":"Brukinsa","share_pct":14.2},{"name":"Jakafi","share_pct":10.8},{"name":"Cabometyx","share_pct":10},{"name":"Calquence","share_pct":7.9},{"name":"Tagrisso","share_pct":6.1},{"name":"Ibrance","share_pct":5.8},{"name":"Bosulif","share_pct":5.5},{"name":"Verzenio","share_pct":4.7},{"name":"Sprycel","share_pct":4.5},{"name":"Imatinib Mesylate","share_pct":3.7},{"name":"Vonjo","share_pct":3.2}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":34.8,"classes_total":5,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":29.4,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":23},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":5.2,"drugs":[{"name":"Palonosetron hcl","share_pct":79.3},{"name":"Ondansetron hydrochloride","share_pct":19.3},{"name":"Ondansetron Odt","share_pct":1},{"name":"Ondansetron Hcl","share_pct":0.4}],"max_beneficiaries":null}]},{"area":"Musculoskeletal","share_pct":14,"classes_total":3,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":13.8,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":43},{"class":"Bisphosphonate","setting":"administered","share_pct":0.2,"drugs":[{"name":"Zoledronic acid","share_pct":100}],"max_beneficiaries":21}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":99.9,"facility_pct":0.1},"source":"medicare"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"publications":{"total":0,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.3009","status":"verified"},{"title":"Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial","year":2025,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2024-010777","status":"verified"},{"title":"298MO Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC","year":2025,"journal":"ESMO Open","source_url":"https://doi.org/10.1016/j.esmoop.2025.104870","status":"verified"},{"title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","year":2024,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2024.08.2239","status":"verified"},{"title":"RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.02110","status":"verified"}],"source":"works"},"recognition":{"education":{"total":3,"shown":3,"rows":[{"value":"Medical school: Christian Medical College, Vellore (1989)","source_url":"https://www.providence.org/doctors/profile/156969-arvind-chaudhry","status":"verified","collected_at":"2026-10-28"},{"value":"MD","source_url":"https://www.providence.org/doctors/profile/156969-arvind-chaudhry","status":"verified","collected_at":"2026-10-28"},{"value":"PhD (institution and field not stated on the profile page)","source_url":"https://www.providence.org/doctors/profile/156969-arvind-chaudhry","status":"provisional","collected_at":"2026-10-28"}]}},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":267,"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-28"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}